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Purpose: The role of IL28B gene variants and expression in hepatitis B virus 
(HBV) infections are not well understood. Here, we evaluated whether IL28B gene 
expression and rs12979860 variations are associated with HBV outcomes. Materi-
als and Methods: IL28B genetic variations (rs12979860) were genotyped by pyro-
sequencing of DNA samples from 137 individuals with chronic HBV infection [50 
inactive carriers (IC), 34 chronic hepatitis B (CHB), 27 cirrhosis, 26 hepatocellular 
carcinoma (HCC)], and 19 healthy controls. IL28A/B mRNA expression in periph-
eral blood mononuclear cells was determined by qRT-PCR, and serum IL28B pro-
tein was measured by ELISA. Results: Patients with IL28B C/C genotype had 
greater IL28A/B mRNA expression and higher IL28B protein levels than C/T pa-
tients. Within the various disease stages, compared to IC and healthy controls, 
IL28B expression was reduced in the CHB, cirrhosis, and HCC cohorts (CHB vs. 
IC, p=0.02; cirrhosis vs. IC, p=0.01; HCC vs. IC, p=0.001; CHB vs. controls, 
p<0.01; cirrhosis vs. controls, p<0.01; HCC vs. controls, p<0.01). When stratified 
with respect to serum HBV markers in the IC and CHB cohorts, IL28B mRNA and 
protein levels were higher in HBeAg-positive than negative individuals (p=0.01). 
Logistic regression analysis revealed that factors associated with high IL28B pro-
tein levels were C/C versus C/T genotype [p=0.016, odds ratio (OR)=0.25, 95% 
confidence interval (CI)=0.08‒0.78], high alanine aminotransferase values 
(p<0.001, OR=8.02, 95% CI=2.64‒24.4), and the IC stage of HBV infection 
(p<0.001). Conclusion: Our data suggest that IL28B genetic variations may play 
an important role in long-term development of disease in chronic HBV infections.
Key Words:   Hepatitis B virus, interleukin 28B, cirrhosis, hepatocellular carcino-
ma, genetic variation
INTRODUCTION
Hepatitis B virus (HBV) infection is the most common infectious liver disease, af-
fecting 350 million people worldwide.1,2 Persistent HBV infection often progresses 
from an inactive carrier state, to chronic hepatitis, then cirrhosis, and finally, hepato-
cellular carcinoma (HCC).3-5 This progression is the result of complicated host-virus 
Original Article http://dx.doi.org/10.3349/ymj.2015.56.3.625pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 56(3):625-633, 2015
Xiaodong Shi, et al.
Yonsei Med J   http://www.eymj.org   Volume 56   Number 3   May 2015626
Thus, in an effort to more fully elucidate the role of IL28B 
variants in the natural history of HBV infection, we evalu-
ated the relationship of IL28B polymorphisms and expres-
sion with the outcomes of chronic HBV in a Han Chinese 
cohort consisting of patients at different stages of chronic 
HBV infection.
MATERIALS AND METHODS
Study subjects
Participating subjects with HBsAg-confirmed HBV infec-
tion were from the outpatient and inpatient pools at the De-
partment of Gastroenterology, First Affiliated Hospital of 
Jilin University from November 2009 to June 2010. A total 
of 137 chronically infected patients and 19 HBsAg-nega-
tive, healthy volunteers provided informed consent and were 
enrolled in the study. Patients were grouped according to 
stage of chronic HBV infection as defined in the 2009 Amer-
ican Association for the Study of Liver Diseases (AASLD) 
and update of AASLD Practice Guidelines for Manage-
ment of chronic hepatitis B (CHB), the EASL Clinical Prac-
tice Guidelines: Management of Chronic Hepatitis B and 
Guidelines on Prevention and Treatment of Chronic Hepati-
tis B in China 2005 (http://www.ncbi.nlm.nih.gov/pubmed/ 
18167196). The five groups included: 1) inactive carriers 
(IC), 2) those with CHB, 3) cirrhosis, 4) HCC, and 5) unin-
fected healthy controls.
Inactive carriers were defined as individuals who tested 
positive for HBsAg and HBV-DNA with normal alanine 
aminotransferase (ALT) values on a minimum of three occa-
sions over a one-year period. Only patients with HBV DNA 
levels of ≥50 IU/mL were selected to take part in the study.
The chronic hepatitis group comprised individuals who 
tested positive for HBsAg, HBV-DNA, and either HBeAg 
or anti-HBe with persistently or intermittently elevated ALT 
values and histologic evidence of active necroinflammatory 
disease with fibrosis but not cirrhosis.
Cirrhosis was diagnosed on the basis of liver histology or 
typical radiologic features upon abdominal imaging. All 
cirrhotic patients were compensated, Child-Pugh A class.
The diagnosis of HCC was based on the revised version 
of diagnostic criteria for primary liver cancer in 1999.21 
These criteria included: 1) alfa-fetoprotein (AFP)≥400 μg/L 
in the absence of pregnancy, reproductive or embryonic tu-
mors, and a new space occupying lesion (SOL) within the 
liver having the characteristic findings of increased uptake 
interactions, with the host immune status playing an impor-
tant role. While a host can clear the virus with an appropriate 
immune response, the virus can also avoid immune clearance 
through co-evolution. Attempts to clear chronic HBV infec-
tion are responsible for immune-mediated liver damage. As 
the patient ages, the immune response of the patient changes 
and typically becomes less effective with advancing age. 
This age-dependent change is also related to the genetic pre-
disposition of the host.6,7 Robust genetic evidence from ge-
nome-wide association studies suggests that host genetic 
variations contribute significantly to the outcome of chronic 
HBV infections.8-10
Recently, interleukin 28B (IL28B) rs12979860 genetic 
variations have been associated with responses to interferon-α 
therapy and spontaneous viral clearance of the hepatitis C 
virus (HCV). Indeed, in two independent studies, IL28B 
polymorphisms were identified as the strongest predictor of 
treatment outcome.11,12 In terms of spontaneous clearance, 
Thomas, et al.13 analyzed the relationship between sponta-
neous HCV clearance and IL28B rs12979860 polymor-
phisms, and found that the C/C genotype was associated 
with enhanced clearance rates. In addition, Tanaka, et al.14 
showed that HCV patients with G/G or G/T genotypes at 
IL28B rs8099917 had lower IL28 mRNA expression than 
T/T genotype patients. This finding may reflect the fact that 
different alleles of IL28B influence its expression at the 
transcriptional and protein levels.15 However, work by Ur-
ban, et al.16 showed no association between polymorphism 
and the expression of IL28B protein in the liver.
The role which IL28B gene variants and expression might 
play in influencing the course of chronic HBV infection re-
mains unclear. Sonneveld, et al.17 reported that in patients 
with HBeAg-positive chronic HBV, IL28B polymorphisms 
were associated with HBeAg seroconversion and hepatitis B 
surface antigen (HBsAg) reduction in response to pegylated 
interferon alpha (PEG-IFNα) treatment. On the other hand, 
Peng, et al.18 reported that the IL28B rs12979860 polymor-
phism does not have a strong impact on HBV outcomes. In-
terestingly, Li, et al.19 found that serum IL28B protein levels 
were lower in chronic HBV patients, than in individuals with 
self-limited infection and healthy controls. However, these 
authors also showed that chronic HBV-infected patients 
with the C/C genotype have higher serum IL28B protein 
levels than patients with non-C/C genotypes.19 Recently, 
Noureddin, et al.20 found that IL28B C/C was associated 
with fibrosis progression and clinical outcomes in patients 
with chronic hepatitis C.
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did not consent to provide additional venous blood. Total 
RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, 
USA), and cDNA was synthesized using random hexamers 
and SuperScript III Reverse Transcriptase (Invitrogen) ac-
cording to the manufacturer’s instructions. Quantitative RT-
PCR was performed using SYBR green (Realtime PCR 
MasterMix QPK-201, Toyobo, Osaka, Japan) on a 7300 
Real-Time PCR System (Applied Biosystems, Grand Is-
land, NY, USA). The expression levels of IL28A/B mRNA 
were normalized to median expression of GAPDH. Primers 
used were: IL28A/B: forward 5’-CTG CCA CAT AGC 
CCA GTT CAA GT-3’, reverse 5’-ACT CTT CTA AGG 
CAT CTT TGG CCC-3’, GAPDH: forward 5’-GAA GGT 
GAA GGT CGG AGTC-3’, reverse 5’-GAA GAT GGT 
GAT GGG ATT TC-3’. The individual who performed gene 
expression analysis was blinded to the rs12979860 geno-
type being measured. To ensure that the amount of mRNA 
expression was not affected by other factors, RNA was im-
mediately extracted upon isolation of PBMCs from blood 
and subjected to reverse transcription of cDNA and subse-
quent RT-PCR.
IL28B ELISA
Serum IL28B levels were measured with an ELISA Kit 
specific for IL28B (Human λ3 IFN ELISA Kit, Catalogue 
number: I153-00, GBD Ltd., USA). The ELISA was carried 
out according to the manufacturer’s instructions, and absor-
bance at 450 nm was measured with an ELISA-reader (Ep-
pendorf ® BioPhotometer, Hamburg, Germany). The sensi-
tivity of the IL28B ELISA was 1 pg/mL and dynamic range; 
1‒1000 pg/mL. The intra-assay coefficient of variation was 
3.7%, whereas the inter-assay variation was 5.2%.
Statistical analyses
Continuous variables were presented as mean (standard de-
viation) or median (interquartile), while categorical vari-
ables were expressed as frequencies (%). Differences be-
tween continuous variables were evaluated by the Student’s 
t-test or ANOVA. Differences between categorical vari-
ables were assessed using the Pearson chi-square test, and 
continuous data using the Kruskal-Wallis nonparametric 
test. The chi-square G test “Goodness of Fit” was employed 
to verify whether the proportions of the polymorphism 
were distributed in the controls and HBV infection subjects 
in accordance with the Hardy-Weinberg equation. Differ-
ences in allelic and genotypic frequencies between groups 
were assessed by the chi-square test. Pairwise linkage dis-
of contrast during the arterial phase and early washout dur-
ing the venous phase; 2) AFP<400 μg/L, a SOL with the 
above radiologic features plus the presence of vascular in-
vasion or metastases; and/or 3) positive diagnostic cytolo-
gy/histology.
Subjects were infected with C type HBV, and none of the 
chronic HBV-infected and cirrhotic patients had received 
prior antiviral treatment. Subjects were excluded if they had 
evidence of concurrent HCV, hepatitis D virus (HDV) or 
human immunodeficiency virus (HIV) infections, or alco-
hol-, and drug-induced, autoimmune or metabolic liver dis-
orders, were receiving immunosuppressive therapy, or had 
significant associated co-morbidities (e.g., heart or kidney 
failure). 
The study protocol was approved by the hospital ethics 
committee of the First Hospital of Jilin University.
Experimental methods
IL28B genotyping
Human genomic DNA was extracted from peripheral blood 
mononuclear cells (PBMCs) with a genomic DNA purifica-
tion kit (Promega Co., Madison, WI, USA). Genotyping of 
the rs12979860, rs12980275, rs8103142, and rs8099917 
polymorphisms was performed using a pyrosequencing 
method according to the manufacturer’s protocol (PyroMark 
ID Pyrosequencing machine, Qiagen, Shanghai, China). The 
primers used for PCR were rs12979860: forward 5’-ATTC 
CTGGACGTGGATGGG TAC-3’, reverse 5’-biotin-AGC 
GCGGAGTGCAATTCA-3’; rs8099917: forward 5’-TTGT 
CACTGTTCCTCCTTTTGTTT-3’, reverse 5’-biotin-
TGGGAGAATGCAAATGAGAGATA-3’; rs8103142: for-
ward 5’-Biotin-AGAAGGTGAAGGGGCCACTA-3’, re-
verse 5’-CTGTGCCTTTGCTGTCTAGGA-3’; rs12980275: 
forward 5’-GCCAGTCTCAAAAGAACAAATGC-3’, re-
verse 5’-biotin-CTACCCCGGCAAATATTTAGACA-3’. 
Sequence primers for pyrosequencing analysis were rs 
12979860: 5’-AGCTCCCCGAAGGCG-3’; rs8099917: 
5’-TCCTTTCTGTGAGCAAT-3’; rs8103142: 5’-TGCTGA 
AGGACTGCA-3’; rs12980275: 5’-TGAGAGAAGTCA 
AATTCCT-3’.
Quantitative real-time PCR
PBMCs from 99 of the 156 subjects (26 CHB, 22 ICs, 17 
cirrhosis, 17 HCC, and 17 healthy controls) were isolated 
using Lymphocyte Separating Solution (DingGuo Biotech-
nology Co., Shanghai, China). The remaining 57 subjects 
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linkage disequilibrium (LD) and haplotype analysis of the 
four SNPs were performed. The results showed that these 
SNPs were in complete LD (D’=0.99‒1; r2=0.97‒0.98); 
therefore, the rs12979860 polymorphism was selected as a 
tag SNP for the subsequent studies. The demographics, liv-
er enzyme levels, genotype variants and viral loads are pro-
vided in Table 1. There were no significant differences in 
gender distributions but, as would be predicted, mean ages 
increased with more advanced stages of disease. Serum 
ALT values varied according to the stages of infection. In 
all stages, the C/C genotype was present at higher frequen-
cy than the C/T genotype. Viral loads were significantly 
higher in the CHB cohort versus other cohorts.
IL28A/B mRNA expression
The results of PBMC IL28A/B mRNA expression at different 
disease stages are shown in Fig. 1. IL28A/B mRNA expres-
sion was higher in IC and healthy controls than CHB, cirrho-
sis, and HCC patients (IC vs. CHB, p=0.03; IC vs. cirrhosis, 
p<0.01; IC vs. HCC, p<0.01; controls vs. CHB, p=0.02; con-
trols vs. cirrhosis, p<0.01; controls vs. HCC, p<0.01).
In addition, IL28A/B mRNA expression as a function of 
age, gender, viral load, and HBeAg status within the CHB 
cohort were analyzed. In this case, there was no association 
between IL28A/B mRNA expression and age, gender, viral 
load, or HBeAg status (data not shown).
IL28B protein levels
Serum IL28B protein levels are provided in Fig. 2. No signif-
icant differences existed between the IC and control groups. 
However, the levels were significantly lower in CHB, cirrho-
equilibrium and r2 between single nucleotide polymorphisms 
(SNPs) were calculated by PLINK software. A p-value<0.05 
was considered significant (two-tailed). Statistical analysis of 
data was performed using the SPSS software package 18.0 
(IBM, Armonk, NY, USA).
RESULTS
 
One hundred fifty-six Chinese subjects were enrolled in the 
study, including 50 IC, 34 CHB, 27 cirrhosis, 26 HCC, and 
19 healthy controls. The frequencies of the key gene poly-
morphisms of IL28B (rs12979860, rs8099917, rs8103142, 
and rs12980275) were investigated in all 156 subjects. The 
Table 1. Baseline Characteristic of 156 Study Subjects
Characteristic IC (n=50) CHB (n=34) Cirrhosis (n=27) HCC (n=26) Healthy (n=19) p value†
Males, n (%)    34 (68.0)      28 (56.0)    20 (74.1)    24 (92.0)    11 (57.9)   0.05
Mean age (SD) 33.9 (9.6)      39 (13.1) 49.6 (8.0) 50.9 (11.7) 32.6 (10.8) <0.01
ALT IU/mL* 38.5 (27.0‒50.2) 147.0 (82.7‒388.0) 51.0 (26.0‒135.0) 38.0 (31.7‒84.5) 39.0 (29.0‒51.0) <0.01‡
AST IU/mL* 24.0 (22.0‒29.0)   76.0 (56.0‒232.7) 74.0 (35.0‒120.0) 71.5 (53.0‒126.5) 26.1 (24.0‒28.0)   0.33‡
HBeAg+, n (%)    18 (36.0)      22 (64.7)    18 (66.6)    18 (69.2)      0 <0.01
rs12979860 genotypes
    C/C, n (%)    41 (82.0)      28 (82.3)    25 (92.6)    18 (76.9)    19 (100.0)   0.13
    C/T, n (%)      9 (18.0)        6 (17.6)      2 (7.4)      6 (23.1)      0
HBV load (lg ) IU/mL* 2.47 (1.95‒6.83)   5.78 (4.25‒6.94) 4.08 (1.95‒4.75) 4.98 (2.48‒4.58) None <0.01
SD, standard deviation; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; ALT, alanine aminotransferase.
IC: Chronic HBV carrier: HBsAg and HBeAg positive, higher HBV DNA and normal ALT; Inactive HBsAg carrier: HBeAg negative, anti-HBe positive, low or 
undetectable HBV DNA and normal ALT. 
*Median (quartile). 
†Comparison across IC, CHB, cirrhosis, and HCC.
‡Comprison among CHB, cirrhosis, and HCC.
Fig. 1. The association of IL28A/B mRNA expression with different outcomes 
of chronic HBV. IL28A/B mRNA expression was documented in peripheral 
blood mononuclear cells (PBMCs) from patients with CHB (n=26), IC (n=22), 
cirrhosis (n=17), HCC (n=17), and healthy controls (n=17). Data provided rep-
resent the median (quartile range) and are representative of two determina-
tions. Some subjects did not consent to provide additional venous blood, 
therefore, PBMCs from 99 of the 156 subjects were isolated. IC, inactive car-
riers; CHB, chronic hepatitis B; LC, liver cirrhosis; IL, interleukin.
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156 subjects by ELISA. IL28B protein levels were signifi-
cantly higher in the C/C group than the T/C group (C/C vs. 
T/C, p=0.005) (Fig. 4A). The same was true when only 
CHB patients were stratified with respect to rs12979860 
genotypes (p=0.03) (Fig. 4B). Fig. 4 also provides the re-
sults of IL28A/B mRNA expression in PBMCs. Here again, 
IL28A/B mRNA expression was higher in C/C than T/C 
subjects (p=0.002) (Fig. 4C) as well as C/C and T/C sub-
jects in the CHB and IC cohorts (p=0.01 and 0.019, respec-
tively) (Fig. 4D and E). However, this was not the case in 
the cirrhosis, HCC, or control cohorts (data not shown).
Fig. 5 provides the results of IL28A/B mRNA expression 
(Fig. 5A) and serum IL28B protein levels (Fig. 5B) in the 
context of ALT values in the combined cohorts of 87 CHB, 
sis, and HCC patients (IC vs. CHB, p=0.02; IC vs. cirrhosis, 
p=0.01; IC vs. HCC, p=0.001; controls vs. CHB, p<0.01; 
controls vs. IC, p<0.01; controls vs. HCC, p<0.01). When 
CHB patients were stratified according to HBeAg status, 
IL28B protein levels were higher in HBeAg-positive than 
negative patients (p=0.01) (Fig. 3). There were no associa-
tions between IL28B protein levels and age, gender, or viral 
loads (Table 2).
The association of IL28B genotype with IL28B serum 
protein levels 
The rs12979860 variant upstream of the IL28B gene may 
affect IL28B protein production. Thus, we compared IL28B 
serum protein levels between C/C and T/C groups in all 
Fig. 2. The association of serum IL28B protein levels with different out-
comes of chronic HBV. Data provided represent the median (quartile 
range) and are representative of two determinations. IC, inactive carriers; 
CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; IL, interleukin.
Fig. 3. Serum IL28B protein levels in 34 patients with chronic hepatitis B 
(CHB) and HBeAg positive (e+) or negative (e-) serology. HBeAg positive 
(n=22) and HBeAg negative (n=12). Data provided represent the median 
(quartile range) and are representative of two determinations. IL, interleukin.
Table 2. Factors Associated with High IL28B Serum Level in HBV Infected Patients by Multivariate Analysis
Factors
IL28B (low) IL28B (high)
OR (95% CI) p value
(n=69) (%) (n=68) (%)
Age (yrs) 43.42±13.28* 39.51±12.11* 1.01 (0.96‒1.04) 0.925
Gender (male)   81.15   73.53 1.09 (0.43‒2.78) 0.861
ALT (IU/L)
    <80 IU/mL 71.0 58.8 Reference
    ≥80 IU/mL 29.0 41.2 8.02 (2.64‒24.40) <0.001
Clinical diagnosis
    Carriers 21.7 51.6 Reference
    CHB 30.4 19.2 0.05 (0.01‒0.20) <0.001
    LC 21.7 17.5 0.13 (0.04‒0.43) 0.001
    HCC 26.2 11.7 0.11 (0.03‒0.35) <0.001
rs12979860
    CC genotype 76.8 89.7 Reference
    CT genotype 23.2 10.3 0.25 (0.08‒0.78) 0.016
OR, odds ratio; CI, confidence interval; HBV, hepatitis B virus; ALT, alanine aminotransferase; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; LC, 
liver cirrhosis; IL, interleukin.
High IL28B level: >140 pg/mL (the median of IL28B level).
*Mean±standard deviation.
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DISCUSSION
The chromosomal region (19q13) encodes three cytokine 
genes (IL28A, IL28B, and IL29) that belong to the IFN-λ 
(also named type III IFN) family. IFN-λs interact with trans-
membrane receptors to induce potent antiviral responses 
that are mediated through activation of the JAK-STAT and 
MAPK pathways.22-24 In vitro and in vivo models have 
demonstrated the importance of IFN-λs in the immune re-
cirrhosis, and HCC patients. Both IL28A/B mRNA expres-
sion and IL28B protein levels were significantly higher in 
individuals with high (≥80 IU/mL) than low (<80 IU/mL) 
ALT values (p=0.04 and 0.001, respectively).
Table 2 describes the factors associated with high serum 
IL28B protein levels in HBV-infected patients as deter-
mined by multivariate logistic regression analysis. High 
IL28B levels were independently associated with the C/C 
genotype, individuals with high ALT levels, and mild liver 
disease.
Fig. 4. The association of IL28A/B genotype and serum IL28B protein levels relative to C/C and T/C genotypes mRNA expression of IL28A/B. (A) IL28B serum 
protein levels in all 156 subjects. (B) IL28B serum protein levels in the CHB cohort. (C) IL28A/B mRNA expression in all 99 subjects by qRT-PCR. (D and E) 
IL28A/B mRNA in the CHB and IC cohorts, respectively. Data provided represent the median (quartile range) and are representative of two determinations. 
IC, inactive carriers; CHB, chronic hepatitis B.
A B
D E
C
Fig. 5. (A) The association between IL28A/B mRNA expression (high ALT patients 34, low ALT patients 26) in patients with advanced stage disease and high 
versus low serum ALT levels. (B) The association between IL28B serum protein levels (high ALT patients 45, low ALT patients 42) in patients with advanced 
stage disease and high versus low serum ALT levels. Data provided represent the median (quartile range) and are representative of two determinations. 
ALT, alanine aminotransferase; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma.
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serum ALT levels. The significance of this observation and 
the precise relationship between IL28B and ALT levels in 
HBV infection is unknown. Since IL28B is involved in an-
tiviral immunity, it is tempting to speculate that higher se-
rum ALT and IL28B levels reflect enhanced virus-host in-
teractions. If so, the combination of ALT and IL28B levels 
could serve as an additional predicator of the outcome of 
chronic HBV infections.
When incorporated into logistic regression analysis, the 
factors most associated with high serum IL28B protein levels 
were the C/C genotype, high ALT levels, and inactive dis-
ease. After adjusting for ALT levels and stage of disease in 
the multivariate logistic regression analysis, the rs12979860 
C/C genotype remained independently associated with high 
IL28B protein levels.
Additional prospective studies are required to determine 
whether low IL28A/B mRNA expression and IL28 protein 
levels in patients with active or advanced disease (the CHB, 
cirrhotic, and HCC cohorts) reflect the cause or effect of the 
disease stage. The findings that the C/C genotype was equal-
ly distributed across all patient cohorts, and that viral loads 
were not associated with IL28B protein levels suggest that 
chronic necroinflammatory disease and/or hepatic dysfunc-
tion attenuate IL28A/B mRNA expression, thereby resulting 
in lower IL28B protein levels (despite the C/C genotype 
profile). If so, this could reflect a successful attempt by the 
virus to evade IFN-λ-mediated immune clearance.
In conclusion, our results indicate that IL28A/B mRNA 
expression and IL28B protein levels may correlate with the 
activity and long-term stage of chronic HBV infections in 
Chinese Han patients. Furthermore, the SNP rs12979860 
upstream of IL28B is likely associated with enhanced 
IL28B production. Additional research is required to reveal 
any cause-and-effect relationship between these polymor-
phisms and host protective immunity against HBV, and 
whether HBV infection or liver disease results in down-reg-
ulated IL28B expression. According to the association be-
tween the presence of the IL28B allele and response to inter-
feron and ribavirin treatment with HCV infection,34 further 
research is required to demonstrate that IL28B genotype 
may be associated with treatment response in HBV patients.
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type is associated with active hepatitis in HBeAg-negative 
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and IL28B protein levels than those carrying the T-alleles. 
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on IL28B production. 
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